Nordic Life Science 1
SUBSCRIBE TO NORDIC LIFE SCIENCE INSPIRING BUSINE
SS & INNOVATION nordiclifescience.org/subscribe P H A S E I I A Spago Nanomedical initiates clinical trial in endometriosis The company has received regulatory approval to initiate a phase IIa clinical study with its MRI contrast agent SN132D in endometriosis. THE PHASE IIA clinical trial is an open label, proof-of-concept study concerning efficacy of the novel intravenous contrast agent SN132D in patients with supected endometriosis. The study will include up to 18 patients. “We are very pleased that SPAGOPIX-01 meets the primary objectives set out for the study and that the results with SpagoPix in breast cancer provide a clinical validation of our nanomedical platform. Based on ongoing discussions with potential partners and experts in the field, we have decided to focus our resources within the SpagoPix program on endometriosis, a severely undertreated disease affecting up to 10 percent of women of reproductive age,” says Mats Hansen, CEO at Spago Nanomedical. “Endometriosis represents a very large indication of major unmet medical need for better imaging diagnostics which current contrast agents and other diagnostics are not able to fulfill.” The study will evaluate the safety and MRI enhancing properties of SN132D in participants with suspected endometriosis. Comparisons will be made to transvaginal ultrasound and conbentional MRI in order to consider the diagnostic potential of SN132D in endometriosis. GET THE FULL LIFE SCIENCE PICTURE: Sign up to our weekly newsletter – Free of charge! SIGN UP TODAY AT: nordiclifescience.org egen-annons-halvsida-stående.indd 1 2023-02-22 13:10